Once considered to act primarily through reductions in albuminuria, GLP-1RAs now have dedicated hard-endpoint evidence: in the FLOW trial, semaglutide reduced the primary composite kidney outcome ( 50% eGFR decline, kidney failure, or kidney or cardiovascular death) by 24% (hazard ratio 0.76, 95% CI 0.660.88) in type 2 diabetes and CKD and slowed eGFR decline [48, 49]
Readers wanting the brand's full marketing copy should visit glpatch.shop
Knowing how to transition between different semaglutide formats without disrupting your protocol is a practical skill that comes up more often than you might expect
GLP-1 Weightloss Oct 6, 2025 2 min read If youve been searching for a safe, effective, and sustainable way to lose weight, Tirzepatide might be your breakthrough
Ndulos Tiroideos: Diagnstico y Tratamiento Diagnstico y Tratamiento El diagnstico de los trastornos tiroideos generalmente involucra anlisis de sangre para medir los niveles de TSH, T3 y T4
The primary endpoint was change in HFF
